Figure 3. Risk for Time to First Cardiovascular Disease (CVD) Event (Using Cox Proportional Hazards Model Analysis) and Total CVD Events (Using Shared Frailty Model Analysis) Associated With SGLT2i vs DPP4i Use in Overall Patient Cohort (N = 1632).

DPP4is represents dipeptidyl peptidase 4 inhibitors: SGLT2is, sodium-glucose cotransporter 2 inhibitors.

^aEvents are the first or repeat CVD events, and rates (%) were calculated as the total number of events divided by the total number of patients in each treatment group.

^bComposite CVD included atrial fibrillation, coronary heart disease, heart failure, hemorrhagic stroke, ischemic stroke, myocardial infarction, and transient ischemic attack.

^cSince no recurrent transient ischemic attacks occurred in the study follow-up period, the analysis for this event was not performed.